Dnl921
Healthy Participants, Alzheimer's Disease
Phase I
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
Aug 06, 2026
―
Dnl126
Mucopolysaccharidosis Type Iiia
Phase I/II
Active Not Recruiting
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
Dec 04, 2023
―
Idursulfase, Tividenofusp Alfa
Mucopolysaccharidosis Ii
Phase II/III
Recruiting
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
May 09, 2022
Tividenofusp Alfa
Mucopolysaccharidosis Ii
Phase I/II
Active Not Recruiting
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
Jan 28, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Denali Therapeutics (4DN) have in its pipeline
4DN is currently developing the following drugs: Dnl921, Dnl952, Dnl628. These drug candidates are in various stages of clinical development as the company works toward FDA approval.